#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13048	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2515	637.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1626	1626	C	807	C,T,G	805,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	13048	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2515	637.9	0	HET	.	.	.	C611T,A	.	611	611	C	1053	1053	C	851	C,T,A	635,214,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21518	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4051	661.3	0	.	n	.	0	T695C	SNP	695	695	T	1277	1277	C	805	C,G,T,A	801,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21518	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4051	661.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1919	1919	A	881	A	881	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21518	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4051	661.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2553	2553	C	748	C,T,G	743,3,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21518	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4051	661.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3179	3179	T	803	T,C,G	800,1,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21518	23S	2890	2890	99.86	23S.l15.c17.ctg.1	4051	661.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2627	2627	A	682	A,T	681,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2062	folP	852	852	100.0	folP.l6.c17.ctg.1	1953	131.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1249	1251	AGC	215;216;216	A;G;C,A	215;216;215,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3807	176.2	1	SNP	p	S91F	0	.	.	271	273	TCC	788	790	TCC	188;187;187	T,G,A;C;C,A	186,1,1;187;186,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3807	176.2	1	SNP	p	D95G	0	.	.	283	285	GAC	800	802	GAC	198;199;200	G,C;A;C	197,1;199;200	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5400	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3807	176.2	1	SNP	p	D95N	0	.	.	283	285	GAC	800	802	GAC	198;199;200	G,C;A;C	197,1;199;200	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1830	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1632	139.3	1	SNP	p	G45D	1	.	.	133	135	GAC	650	652	GAC	227;226;227	G,T;A,C;C	226,1;225,1;227	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1070	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1400	95.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4764	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3387	175.2	1	SNP	p	D86N	0	.	.	256	258	GAC	835	837	GAC	212;211;208	G;A,T,C;C,A	212;209,1,1;207,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4764	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3387	175.2	1	SNP	p	S87R	0	.	.	259	261	AGT	838	840	AGT	208;208;205	A;G,T;T	208;207,1;205	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4764	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3387	175.2	1	SNP	p	S87W	0	.	.	259	261	AGT	838	840	AGT	208;208;205	A;G,T;T	208;207,1;205	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4764	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3387	175.2	1	SNP	p	S87I	0	.	.	259	261	AGT	838	840	AGT	208;208;205	A;G,T;T	208;207,1;205	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4764	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3387	175.2	1	SNP	p	S88P	0	.	.	262	264	TCC	841	843	TCC	207;208;206	T;C,G;C	207;207,1;206	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3908	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3070	158.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1789	1791	GGC	207;209;209	G;G,C;C	207;208,1;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1417	1419	GCA	221;219;219	G;C,T;A	221;218,1;219	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1420	1422	ATC	217;216;217	A;T,C,G;C	217;214,1,1;217	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1432	1434	GTG	211;211;212	G;T,G;G,T	211;209,2;211,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1432	1434	GTG	211;211;212	G;T,G;G,T	211;209,2;211,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1936	1938	ACC	193;194;193	A;C;C	193;194;193	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1990	1992	GCG	185;185;183	G;C;G	185;185;183	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1990	1992	GCG	185;185;183	G;C;G	185;185;183	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2113	2115	GGC	203;204;208	G,C;G;C	202,1;204;208	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2122	2124	GGC	209;207;210	G;G;C	209;207;210	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3624	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2722	165.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2140	2142	CCG	212;213;215	C,G,A;C;G	210,1,1;213;215	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5248	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3546	184.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2414	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2151	139.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	723	723	C	198	C	198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	621	623	GGA	220;219;217	G;G;A,G	220;219;216,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	V75I	NONSYN	223	225	GTT	702	704	ATT	206;204;202	A;T;T	206;204;202	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	744	746	AGC	196;195;194	A;G;C	196;195;194	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	V98I	NONSYN	292	294	GTC	771	773	ATC	193;194;192	A,T;T;C,T	192,1;194;191,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	836	837	CG	179;177	C,A;G,T	177,1;174,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	839	841	CAG	184;181;184	C;A,C;G,A,T	183;179,1;180,2,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	843	845	AAA	184;183;182	A;A;A	184;183;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	906	908	GAA	199;200;200	G;A,T,G;A,T	199;198,1,1;199,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	930	932	GCA	186;189;188	G;C,A;A	186;188,1;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1116	1118	TCA	244;244;244	T,G,A;C;A,C	241,2,1;244;243,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1236	1238	CAA	181;180;179	C;A;A	181;180;179	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	.	INDELS	760	762	ACA	1240	1244	ATCAA	175;172;173;172;172	A;T;C;A;A	175;172;173;172;172	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	.	INDELS	763	764	TG	1247	1249	AGT	171;171;172	A;G,A;T	171;170,1;172	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1254	1256	GAT	178;178;177	G;A;T	178;178;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1362	1364	AGT	209;213;214	A;G;T	209;213;214	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1368	1370	GAC	217;219;219	G,T;A;C,T	216,1;219;218,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1371	1373	TAC	222;222;225	T,C;A;C	221,1;222;225	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	1	SNP	p	G120K	1	.	.	358	360	AAG	836	838	CGG	179;177;183	C,A;G,T;G,T	177,1;174,2;181,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	1	SNP	p	A121D	1	.	.	361	363	GAC	839	842	CGC	184;184;182	C;G,A,T;C,A	183;180,2,1;181,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2416	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1795	167.5	1	SNP	p	D121N	0	.	.	361	363	GAC	839	842	CGC	184;184;182	C;G,A,T;C,A	183;180,2,1;181,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	216	porB3	990	161	93.79	porB3.l15.c4.ctg.2	163	46.8	0	.	p	.	0	S273T	NONSYN	817	819	TCG	62	64	ACT	61;61;61	A;C;T	61;61;61	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	216	porB3	990	161	93.79	porB3.l15.c4.ctg.2	163	46.8	0	.	p	.	0	D276S	NONSYN	826	828	GAT	71	73	AGT	61;61;61	A;G;T	61;61;61	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	216	porB3	990	161	93.79	porB3.l15.c4.ctg.2	163	46.8	0	.	p	.	0	K278D	NONSYN	832	834	AAA	77	79	GAC	61;61;61	G;A;C	61;61;61	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	216	porB3	990	161	93.79	porB3.l15.c4.ctg.2	163	46.8	0	.	p	.	0	R279Y	NONSYN	835	837	CGC	80	82	TAC	61;61;61	T;A;C	61;61;61	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8654	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5432	198.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2363	2365	AAT	233;232;230	A;A;T,A	233;232;228,2	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1236	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1509	102.2	1	SNP	p	V57M	1	.	.	169	171	ATG	744	746	ATG	223;223;224	A;T;G	223;223;224	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
